Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.55
Nov 19 • 3:59 PM ET Dollar change+0.09 Percentage change(5.79%)
Aftermarket Close
1.59
Aftermarket • 7:56 PM ET Dollar change+0.04 Percentage change(2.30%)
Index
-
Market Cap
0.52M
Enterprise Value
7.63M
Income
-2.50M
Sales
3.06M
Book/sh
15.04
Cash/sh
5.66
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
45
IPO
May 12, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
0.17
P/B
0.10
P/C
0.27
P/FCF
-
EV/EBITDA
-
EV/Sales
2.49
Quick Ratio
1.23
Current Ratio
1.23
Debt/Eq
0.32
LT Debt/Eq
0.28
Option/Short
No / Yes
EPS (ttm)
-11.61
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
51.07% 21.04%
Sales past 3/5Y
- -
EPS Y/Y TTM
94.98%
Sales Y/Y TTM
143.06%
EPS Q/Q
53.93%
Sales Q/Q
563.79%
Insider Own
2.25%
Insider Trans
0.00%
Inst Own
3.98%
Inst Trans
23.01%
ROA
-18.38%
ROE
-27.22%
ROIC
-18.18%
Gross Margin
-
Oper. Margin
-244.54%
Profit Margin
-81.60%
SMA20
-16.25%
SMA50
-60.45%
SMA200
-89.83%
Trades
Shs Outstand
0.34M
Shs Float
0.33M
52W High
52.00 -97.01%
52W Low
1.13 37.35%
Volatility
17.90% 14.88%
ATR (14)
0.39
RSI (14)
27.07
Beta
2.27
Rel Volume
0.46
Avg Volume
565.77K
Volume
258,741
Perf Week
-12.09%
Perf Month
-36.32%
Perf Quarter
-87.93%
Perf Half Y
-92.18%
Perf YTD
-94.54%
Perf Year
-96.07%
Perf 3Y
-99.38%
Perf 5Y
-99.98%
Perf 10Y
-99.99%
Prev Close
1.47
Price
1.55
Change %
5.79%
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
M.Sc.Mr. Amir Reichman M.B.A.
M.B.A.Mr. Uri Ben-Or CPA
Eng.Mr. Elad Mark B.Sc.
Head of HRGal Ron
Head of Quality Control & GMP AnalyticsMerav Kamensky